Serum cytokine profiles in patients with prostate carcinoma

Tazaki,Eri; Shimizu,Nobuaki; Tanaka,Ryota; Yoshizumi,Masakazu; Kamma,Hiroshi; Imoto,Shigeru; Goya,Tomoyuki; Kozawa,Kunihisa; Nishina,Atsuyoshi; Kimura,Hirokazu

doi:10.3892/etm.2011.286

Serum cytokine profiles in patients with prostate carcinoma

Authors:
- Eri Tazaki
- Nobuaki Shimizu
- Ryota Tanaka
- Masakazu Yoshizumi
- Hiroshi Kamma
- Shigeru Imoto
- Tomoyuki Goya
- Kunihisa Kozawa
- Atsuyoshi Nishina
- Hirokazu Kimura
View Affiliations

Affiliations: Department of Surgery, Kyorin University, School of Medicine, Mitaka-shi, Tokyo 181-8611, Japan, Department of Urology, Gunma Prefectural Cancer Center, Ota-shi, Gunma 373-8550, Japan, Gunma Prefectural Institute of Public Health and Environmental Sciences, Maebashi-shi, Gunma 371-0052, Japan, Department of Pathology, Kyorin University, School of Medicine, Mitaka-shi, Tokyo 181-8611, Japan, Yamagata Prefectural Yonezawa Women's Junior College, Yonezawa-shi, Yamagata 992-0025, Japan, Infectious Disease Surveillance Center, National Institute of Infectious Diseases,Musashimurayama-shi, Tokyo 208-0011, Japan
Published online on: June 16, 2011 https://doi.org/10.3892/etm.2011.286
Pages: 887-891

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It has been suggested that various cytokines are associated with the pathophysiology of prostate carcinoma (Pca). We profiled ten cytokines (IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IFN-γ and TNF-α) in the serum levels of 11 patients with organ-confined Pca, 15 with advanced Pca without cachexia, 8 with advanced Pca with cachexia (cachexia group) and 5 healthy males as controls. Cytokines were measured using a highly sensitive fluorescence microsphere system. Compared to the control group, serum levels of all cytokines were significantly higher in the cachexia group, and six cytokines (IL-1β, IL-2, IL-8, IL-12, TNF-α and IFN-γ) were significantly higher in the group with advanced Pca without cachexia. In the group with organ-confined Pca, only IL-1β and IL-12 levels were significantly higher compared to the control group. In the cachexia group, levels of all cytokines apart from TNF-α were significantly higher compared to the group with organ-confined Pca, and levels of four cytokines (IL-2, IL-4, IL-8 and IL-10) were significantly higher compared to the group with advanced Pca without cachexia. These results indicate that i) an aberrance imbalance of cytokine production was associated with the pathophysiology of Pca and cachexia, ii) cytokine profiles in Pca patients were distinct by disease stage, and iii) IL-1β and IL-12 may be applicable as early diagnostic indicators.

View Figures

View References

1.	Nelson WG: Prostate cancer prevention. Curr Opin Urol. 17:157–167. 2007. View Article : Google Scholar
2.	Eble JN, Sauter G, Epstein JI and Sesterhenn IA: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs; World Health Organization Classification of Tumours. International Agency for Research on Cancer (IARC) Press; Lyon: 2004
3.	Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol. 2:533–543. 2001.PubMed/NCBI
4.	Argilés JM, Meijsing SH, Pallarés-Trujillo J, Guirao X and López-Soriano FJ: Cancer cachexia: a therapeutic approach. Med Res Rev. 1:83–101. 2001.
5.	Tisdale MJ: Biology of cachexia. J Natl Cancer Inst. 89:1763–1773. 1997. View Article : Google Scholar : PubMed/NCBI
6.	Davis MP and Dickerson D: Cachexia and anorexia: cancer’s covert killer. Support Care Cancer. 8:180–187. 2000.
7.	Smith KC, Bateman AC, Fussell HM and Howell WM: Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur J Immunogenet. 31:167–173. 2004. View Article : Google Scholar : PubMed/NCBI
8.	Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissière F, Laune D, Roques S and Lazennec G: Oestrogen receptor-negative breast cancers exhibit high cytokine content. Breast Cancer Res. 9:R152007. View Article : Google Scholar : PubMed/NCBI
9.	Suzuki S, Mita S, Kamohara H, Sakamoto K, Ishiko T and Ogawa M: IL-6 and IFN-gamma regulation of IL-10 production by human colon carcinoma cells. Int J Oncol. 18:581–586. 2001.PubMed/NCBI
10.	Szaflarska A, Szczepanik A, Siedlar M, Czupryna A, Sierzega M, Popiela T and Zembala M: Preoperative plasma level of IL-10 but not of proinflammatory cytokines is an independent prognostic factor in patients with gastric cancer. Anticancer Res. 29:5005–5012. 2009.PubMed/NCBI
11.	Kuroda K, Nakashima J, Kanao K, Kikuchi E, Miyajima A, Horiguchi Y, Nakagawa K, Oya M, Ohigashi T and Murai M: Interleukin 6 is associated with cachexia in patients with prostate cancer. Urology. 69:113–117. 2007. View Article : Google Scholar : PubMed/NCBI
12.	Tisdale MJ: New cachexic factors. Curr Opin Clin Nutr Metab Care. 3:253–256. 1998. View Article : Google Scholar
13.	Nakashima J, Tachibana M, Ueno M, Miyajima A, Baba S and Murai M: Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer. Clin Cancer Res. 7:1743–1748. 1998.PubMed/NCBI
14.	Pfitzenmaier J, Vessella R, Higano CS, Noteboom JL, Wallace D Jr and Corey E: Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer. 97:1211–1216. 2003. View Article : Google Scholar : PubMed/NCBI
15.	Filella X, Alcover J, Zarco MA, Beardo P, Molina R and Ballesta AM: Analysis of type T1 and T2 cytokines in patients with prostate cancer. Prostate. 44:271–274. 2000. View Article : Google Scholar : PubMed/NCBI
16.	Wang M, Hu Y and Stearns ME: A novel IL-10 signalling mechanism regulates TIMP-1 expression in human prostate tumour cells. Br J Cancer. 88:1605–1614. 2003. View Article : Google Scholar : PubMed/NCBI
17.	Vindrieux D, Escobar P and Lazennec G: Emerging roles of chemokines in prostate cancer. Endocr Relat Cancer. 3:663–673. 2009. View Article : Google Scholar : PubMed/NCBI
18.	Giri D, Ozen M and Ittmann M: Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol. 159:2159–2165. 2001. View Article : Google Scholar : PubMed/NCBI
19.	Bouraoui Y, Ricote M, García-Tuñón I, Rodriguez-Berriguete G, Touffehi M, Rais NB, Fraile B, Paniagua R, Oueslati R and Royuela M: Pro-inflammatory cytokines and prostate-specific antigen in hyperplasia and human prostate cancer. Cancer Detect Prev. 32:23–32. 2008. View Article : Google Scholar : PubMed/NCBI
20.	Berry SJ, Coffey DS, Walsh PC and Ewing LL: The development of human benign prostatic hyperplasia with age. J Urol. 132:474–479. 1984.PubMed/NCBI
21.	Barnes PJ: The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest. 118:3546–3556. 2008. View Article : Google Scholar : PubMed/NCBI
22.	Kim SJ, Uehara H, Karashima T, McCarty M, Shih N and Fidler IJ: Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice. Neoplasia. 3:33–42. 2001. View Article : Google Scholar : PubMed/NCBI
23.	Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Pettaway CA and Dinney CP: Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res. 6:2104–2119. 2000.PubMed/NCBI
24.	Gelin J, Moldawer LL, Lönnroth C, Sherry B, Chizzonite R and Lundholm K: Role of endogenous tumor necrosis factor α and interleukin 1 for experimental tumor growth and the development of cancer cachexia. Cancer Res. 51:415–421. 1991.
25.	Fandrey J and Jelkmann WE: Interleukin-1 and tumor necrosis factor α inhibit erythropoietin production in vitro. Ann NY Acad Sci. 628:250–255. 1991.
26.	Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G and Anichini A: Interleukin-12: Biological properties and clinical application. Clin Cancer Res. 13:4677–4685. 2007.PubMed/NCBI
27.	Sangro B, Melero I, Qian C and Prieto J: Gene therapy of cancer based on interleukin 12. Currt Gene Ther. 5:573–581. 2005. View Article : Google Scholar : PubMed/NCBI
28.	Mocellin S, Marincola FM and Young HA: Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol. 78:1043–1051. 2005. View Article : Google Scholar : PubMed/NCBI
29.	Quatan N, Meyer B, Bailey M and Pandha H: Persistently high levels of immunosuppressive cytokines in patients after radical prostatectomy. Prostate Cancer Prostatic Dis. 9:420–425. 2006. View Article : Google Scholar : PubMed/NCBI